The bilateral infusions of AB-1005 were well tolerated, without any SAEs linked to the gene therapy or contrast agent.
AskBio Parkinson’s and MSA Scientific chair Krystof Bankiewicz said: “These early findings are encouraging and show AB-1005 to be well tolerated in this study in patients with mild to moderate Parkinson’s disease.
Harnessing Probiotics to Deliver Parkinson’s Disease Treatment
ALZFORUM article: Genetic Findings Link Parkinson’s Disease to Crohn’s Disease, and to Inflammation
